Biotech Values

[DewDiligence]

Is [SNY’s] immediate 4% reduction projection (earnings or revenue, I can't recall?) factoring an enoxaparin price war into it?

By simple arithmetic, the answer is clearly not. The 4% guidance reduction was for 2010 EPS (http://en.sanofi-aventis.com/binaries/20100723_enoxaparine_en_tcm28-28977.pdf ).